Assembly Biosciences, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $72.3M | $28.5M | $7.2M | $0 | $6.3M | $79.1M | $16.0M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $64.8M | $55.9M | $48.9M | $70.0M | $68.5M | $106.8M | $85.8M |
| SG&A Expense | — | $19.6M | $18.0M | $22.9M | $24.1M | $28.8M | $37.1M | $32.9M |
| Operating Income | — | $-12.1M | $-45.4M | $-64.6M | $-94.1M | $-132.7M | $-64.8M | $-102.7M |
| Operating Margin | — | -16.8% | -159.3% | -902.5% | — | -2,121.7% | -81.9% | -643.4% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | $-6.1M | $-39.8M | $-61.2M | $-93.1M | $-132.4M | $-62.2M | $-98.4M |
| Income Tax Expense | — | $0 | $330.0K | $33.0K | $0 | $-2.5M | $0 | $-774.0K |
| Net Income | — | $-6.1M | $-40.2M | $-61.2M | $-93.1M | $-129.9M | $-62.2M | $-97.6M |
| Net Margin | — | -8.5% | -140.9% | -854.8% | — | -2,076.4% | -78.6% | -611.6% |
| EPS (Basic) | — | $-0.55 | $-6.69 | $-13.38 | $-23.08 | $-3.00 | $-1.75 | $-3.72 |
| EPS (Diluted) | — | $-0.55 | $-6.69 | $-13.38 | $-23.08 | $-3.00 | $-1.75 | $-3.72 |
| Shares Outstanding (Basic) | 15.9M | 11.2M | 6.0M | 4.6M | 4.0M | 43.3M | 34.0M | 32.6M |
| Shares Outstanding (Diluted) | 15.9M | 11.2M | 6.0M | 4.6M | 4.0M | 43.3M | 34.0M | 32.6M |
| Dividends Per Share | — | — | — | — | — | — | — | — |